All In Biotech

Drug Trial Radar · NCT02131220

Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

A Randomized, Parallel-controlled, Multi-center Study of the Effects of Intracoronary Recombinant HUman Prourokinase or TIrofiban on the Coronary Flow During Primary PCI for the Acute Myocardial InfartiON

Last checked: Nov 20, 2026Latest source record: Aug 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 362 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

362

Actual

Start

Nov 2015

Primary completion

Aug 2017

Study completion Sep 2017

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether intracoronary selective thrombolysis are more effective than tirofiban on the coronary flow during primary percutaneous coronary intervention for the acute myocardial infarction.

Conditions

  • Myocardial Infarction
  • Percutaneous Coronary Intervention
  • Thrombolytic Therapy

Interventions

  • ProurokinaseDrug

    20mg intracoronary bolus infusion using selective catheter during PCI

  • TirofibanDrug

    10ug/kg intracoronary bolus infusion using selective catheter during PCI

  • normal salineDrug

    intracoronary bolus infusion using selective catheter during PCI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Coronary flow using corrected Thrombolysis In Myocardial Infarction Frame Count (cTFC)Time frame: At the end of Percutaneous Coronary Intervention procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Cardiology, Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.